Concord Historical Cash Flow
| CCM Stock | USD 5.00 0.35 7.53% |
Analysis of Concord Medical cash flow over time is an excellent tool to project Concord Medical Services future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 126.4 M or Total Cash From Financing Activities of 382.5 M as it is a great indicator of Concord Medical ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Concord Medical Services latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Concord Medical Services is a good buy for the upcoming year.
Concord |
About Concord Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Concord balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Concord's non-liquid assets can be easily converted into cash.
Concord Medical Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Concord Medical Services to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Concord Medical operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Concord Medical's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Concord Medical Services current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Concord Medical Services. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. At this time, Concord Medical's Total Cash From Financing Activities is very stable compared to the past year. As of the 7th of February 2025, Change To Inventory is likely to grow to about 53.7 M, while Capital Expenditures is likely to drop about 126.4 M.
Concord Medical cash flow statement Correlations
Click cells to compare fundamentals
Concord Medical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Concord Medical cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Other Cashflows From Financing Activities | 2.4B | 498.3M | 19.9M | 194.8M | 224.1M | 212.9M | |
| Capital Expenditures | 512.9M | 760.6M | 383.8M | 115.7M | 133.1M | 126.4M | |
| Total Cash From Operating Activities | (229.8M) | (359.3M) | (216.7M) | (276.5M) | (248.8M) | (236.4M) | |
| Total Cash From Financing Activities | 1.1B | 642.4M | 383.1M | 257.7M | 296.3M | 382.5M | |
| End Period Cash Flow | 446.4M | 158.9M | 159.3M | 90.4M | 81.4M | 77.3M | |
| Change To Netincome | 174.8M | 32.5M | (145.4M) | 35.1M | 40.4M | 31.6M | |
| Change To Inventory | (14.4M) | (4.4M) | (46.8M) | 44.5M | 51.2M | 53.7M | |
| Change In Cash | 372.1M | (287.5M) | 432K | (68.9M) | (62.0M) | (58.9M) | |
| Stock Based Compensation | 11.1M | 20.6M | 20.6M | 14.7M | (5.9M) | 0.0 | |
| Free Cash Flow | (742.7M) | (1.1B) | (600.5M) | (392.2M) | (353.0M) | (370.6M) | |
| Change In Working Capital | (32.6M) | (115.7M) | (60.2M) | (14.5M) | (16.7M) | (17.5M) | |
| Begin Period Cash Flow | 74.3M | 446.4M | 158.9M | 159.3M | 143.4M | 136.2M | |
| Depreciation | 80.3M | 104.1M | 132.8M | 128.5M | 115.6M | 91.0M | |
| Other Non Cash Items | 119.3M | (90.9M) | 206.2M | (92.8M) | (106.7M) | (101.4M) | |
| Change To Account Receivables | (6.2M) | (64.5M) | 644K | 36.5M | 41.9M | 44.0M | |
| Net Income | (404.0M) | (271.4M) | (489.7M) | (297.7M) | (267.9M) | (254.5M) | |
| Investments | (239.3M) | (566.0M) | (118.8M) | (47.7M) | (42.9M) | (45.1M) | |
| Net Borrowings | 523.3M | 353.1M | 245.5M | 383.1M | 440.6M | 286.7M | |
| Total Cashflows From Investing Activities | (1.1B) | (533.9M) | (566.0M) | (118.8M) | (106.9M) | (112.3M) | |
| Change To Operating Activities | (60.7M) | (79.8M) | (46.9M) | (14.1M) | (16.2M) | (17.0M) | |
| Other Cashflows From Investing Activities | (7.2M) | 193.0M | 265.0M | 68.0M | 78.2M | 82.1M | |
| Change To Liabilities | 3.8M | 95.7M | 69.4M | 170.9M | 196.5M | 206.4M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Concord Medical Services. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Concord Medical. If investors know Concord will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Concord Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.92) | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets | Return On Equity |
The market value of Concord Medical Services is measured differently than its book value, which is the value of Concord that is recorded on the company's balance sheet. Investors also form their own opinion of Concord Medical's value that differs from its market value or its book value, called intrinsic value, which is Concord Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Concord Medical's market value can be influenced by many factors that don't directly affect Concord Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Concord Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Concord Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Concord Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.